Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 2:S0016-5107(25)01782-1.
doi: 10.1016/j.gie.2025.06.045. Online ahead of print.

Endoscopic submucosal resection using a ligation band without injection for rectal neuroendocrine tumors (with video)

Affiliations

Endoscopic submucosal resection using a ligation band without injection for rectal neuroendocrine tumors (with video)

Tomoya Ueda et al. Gastrointest Endosc. .

Abstract

Background and aims: The most appropriate endoscopic resection procedure for small rectal neuroendocrine tumors (NETs) remains unclear. We aimed to evaluate the usefulness of endoscopic submucosal resection using a ligation band (ESMR-L) without submucosal injection compared to ESMR-L with submucosal injection.

Methods: This single-center retrospective study included rectal NETs (≤10 mm) treated with ESMR-L between March 2017 and July 2024. The primary endpoint was sufficient vertical R0 (SVR0) resection, defined as R0 resection with tumor-free vertical margin ≥500 μm.

Results: Of 102 rectal NETs treated with ESMR-L, 71 were resected with injection and 31 without injection. Tumor-free vertical margin distance was significantly greater in ESMR-L without injection (1070 vs 430 μm, P < .001). ESMR-L without injection achieved a significantly higher SVR0 resection rate (67.7% vs 40.8%, P = .018) without an increase in adverse events.

Conclusions: ESMR-L without injection can be simpler and more effective for small rectal NETs than ESMR-L with injection.

PubMed Disclaimer

Conflict of interest statement

Disclosure The following authors disclosed financial relationships: T. Kanesaka has received honoraria from Olympus, AstraZeneca, and AI Medical Service. S. Shichijo has received honoraria from FUJIFILM Medical, Boston Scientific, EA Pharma, AstraZeneca, Daiichi-Sankyo, AI Medical Service, Zeria Pharmaceutical, and Janssen Pharmaceutical. S. Yamamoto has received honoraria from MSD. N. Uedo has received honoraria from Olympus, FUJIFILM Medical, Boston Scientific, Daiichi-Sankyo, Takeda Pharmaceutical, EA Pharma, Otsuka Pharmaceutical, AstraZeneca, Miyarisan Pharmaceutical, AI Medical Service, and MC Medical. R. Ishihara has received honoraria from Olympus, FUJIFILM Medical, Daiichi-Sankyo, Miyarisan Pharmaceutical, AI Medical Service, Astra Zeneca, MSD, and Ono Pharmaceutical. All other authors disclosed no financial relationships.

LinkOut - more resources